Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11505600

Methods of treating skin cancer by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11498970

Human antibodies to the human glucagon receptor and methods of use thereof to lower blood

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11498969

Compositions and methods for treating juvenile idiopathic arthritis

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492392

Polynucleotides encoding anti-C5 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11491222

Method of treating lower back pain

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11491237

Cyclodextrin protein drug conjugates

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485788

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485958

HSD17B13 variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485770

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485793

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479602

Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472870

Pharmaceutical composition for safe and effective treatment of knee and/or hip pain

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472861

Methods for producing aflibercept in chemically defined media having reduced aflibercept v

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464830

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459373

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459374

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453721

Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453714

Human antibodies to influenza hemagglutinin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11446389

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11440950

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439683

Anti-angiogenic therapy of metastatic colorectal cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11434300

Methods and antibody compositions for tumor treatment

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421036

Methods of treating eosinophilic esophagitis by administering an antibody which inhibits i

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11419318

Genetically modified rat comprising a humanized TRKB locus

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted